



PTO/SB/08A (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 9

### Complete if Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk
Art Unit	4647 1649
Examiner Name	Nichols Ballard
Attorney Docket Number	15270J-004743US

### U.S. PATENT DOCUMENTS

Examiner	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KAB	442	6,713,450 B2	03-30-2004	Frangione et al.	
	415	2003/0166558 A1	09-04-2003	Frangione et al.	
	431	2003/0165496 A1	09-04-2003	Basi et al.	
	432	6,562,341 B2	05-13-2003	Prusiner et al.	
	360	2003/0073655 A1	04-17-2003	Chain	
	370	2003/0068325 A1	04-10-2003	Wang	
	440	2003/0068316 A1	04-10-2003	Klein et al.	
	378	2002/0197258 A1	12-26-2003	Ghanbari et al.	
	366	2002/0187157 A1	12-12-2002	Jensen et al.	
	377	2002/0168377 A1	11-14-2002	Schaetzel	
	340	2002/0162129 A1	10-31-2002	Lannfelt	
	395	2002/0160394 A1	10-31-2002	Wu	
	326	2002/0136718 A1	09-26-2002	Raso	
	379	2002/0132268 A1	09-19-2002	Chang et al.	
	365	2002/0133001 A1	09-19-2002	Geffer et al.	
	325	2001/0102261 A1	08-01-2002	Raso	
	362	2002/0094335 A1	07-18-2002	Chalifour et al.	
	306	6,417,178 B1	07-09-2002	Klunk et al.	
	376	2002/0086847 A1	07-04-2002	Chain	
	405	6,399,314 B1	06-04-2002	Krishnamurthy	
	342	2002/0009445 A1	01-24-2002	Du et al.	
	416	6,303,567 B1	10-16-2001	Findeis et al.	
	381	2001/0021769 A1	09-13-2001	Prusiner	
	401	6,284,533 B1	09-04-2001	Thomas	
	345	2002/0077288 A1	06-21-2001	Frangione	
	417	5,985,242	11-16-1999	Findeis et al.	
	346	5,935,927	08-10-1999	Vitek et al.	
	382	5,846,533	12-08-1998	Prusiner	
	321	5,837,672	11-17-1998	Schenk et al.	
	353	5,824,322	10-20-1998	Balasubramanian	
KAB	357	5,776,468 B1	07-07-1998	Hauser et al.	
KAB	380	5,750,361	05-12-1998	Prusiner et al.	
Examiner Signature	K. Ballard		Date Considered	10/3/06	

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 60195301 v1



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2

of

9

### Complete if Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk
Art Unit	1647
Examiner Name	Nichols
Attorney Docket Number	15270J-004743US

KAB	373	5,721,130	02-24-1998	Seubert et al.	
	356	5,622,701	04-22-1997	Berg	
	320	5,593,846	01-14-1997	Schenk et al.	
	358	5,583,112 B2	12-10-1996	Kensil et al.	
	403	5,464,823	11-07-1995	Lehrer et al.	
KAB	402	4,713,366	12-15-1987	Stevens	

### U.S. PATENT DOCUMENTS

Examiner	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KAB	305	09/724,842	11-28-2000	Chalifour et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
KAB	343	EP	1 172 378	A1	01-16-2002			
	441	WO	03/104437	A2	12-18-2003			
	443	WO	03/074081	A1	09-13-2003			
	433	WO	03/020212	A2	03-13-2003			
	351	WO	02/34878	A2	05-02-2002			
	352	WO	02/34777	A1	05-02-2002			
	341	WO	02/03911	A2	04-07-2001			
	344	WO	01/90182	A2	11-29-2001			
	348	WO	01/77167	A2	10-18-2001			
	322	WO	00/72880	A2, A3	12-07-2000			
	323	WO	00/72876	A2, A3	12-07-2000			
	324	WO	00/72870	A1	12-07-2000			
	331	WO	99/06545	A2	11-02-1999			
KAB	383	WO	97/10505	A1	03-20-1997			

Examiner  
Signature

K. Ballard


Date  
Considered

10/3/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 60195301 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/724,319		
		Filing Date	November 27, 2000		
		First Named Inventor	Schenk		
		Art Unit	1647		
		Examiner Name	Nichols		
Sheet	3	of	9	Attorney Docket Number	15270J-004743US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
KAB	391	AGUZZI et al., "Prion research: the next frontiers," <u>Nature</u> , 389:795-798 (1997).	
	393	AKIYAMA et al., "Inflammation and Alzheimer's disease," <u>Neurobiology of Aging</u> , 21:383-421 (2000).	
	372	AKIYAMA et al., "Occurrence of the Diffuse Amyloid $\beta$ -Protein (A $\beta$ ) Deposits With Numerous A $\beta$ -Containing Glial Cells in the Cerebral Cortex of Patients With Alzheimer's Disease," <u>Glia</u> , 25:324-331 (1999).	
	404	BENJAMINI and LESKOWITZ, from <u>IMMUNOLOGY A Short Course</u> , Second Edition, Chapter 4, Antibody Structure, pages 49-65, 1991, published by Wiley-Liss, Inc., New York, New York.	
	418	BORK, P., "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle," <u>Genome Research</u> , 10:398-400 (2000).	
	419	BORK et al., "Go hunting in sequence databases but watch out for the traps," <u>Trends in Genetics</u> , 12(10):425-427 (1996).	
	420	BRENNER, S. E., "Errors in genome annotation," <u>Trends in Genetics</u> , 15(4):132-133 (1999).	
	421	CASTILLO et al., "Amylin / Islet Amyloid Polypeptide: Biochemistry, Physiology, Patho-Physiology," <u>Diabete &amp; Metabolisme (Paris)</u> , 21:3-25 (1995).	
	349	CHECK, "Battle of the Mind," <u>Nature</u> , 422:370-372 (March 2003).	
	332	CHEN et al., "Neurodegenerative Alzheimer-like pathology in PDAPP 717V $\rightarrow$ F transgenic mice," <u>Progress in Brain Research</u> , Van Leeuwen et al. Eds, 117:327-337 (1998).	
	307	CHEN et al., "A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease," <u>Nature</u> , 408(6815):975-9 (2000).	
	333	CONWAY et al., "Acceleration of oligomerization, not fibrillization, is a shared property of both $\alpha$ -synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy," <u>PNAS</u> , 97(2):571-576 (2000).	
KAB	412	DAS et al., "Amyloid- $\beta$ Immunization Effectively Reduces Amyloid Deposition in FcR $\gamma$ Knock-Out Mice," <u>J. Neuroscience</u> , 23(24):8532-8538 (2003).	

Examiner Signature	K. Ballar	Date Considered	10/3/06
-----------------------	-----------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60195301 v1



PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/724,319		
		Filing Date	November 27, 2000		
		First Named Inventor	Schenk		
		Art Unit	1647		
		Examiner Name	Nichols		
Sheet	4	of	9	Attorney Docket Number	15270J-004743US


KAB	436	DICKSON et al., "Neuroimmunology of Alzheimer's disease: a conference report," <u>Neurobiology of Aging</u> , 13(6):793-798 (1992), abstract only	
	390	DIOMEDE et al., "Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes," <u>Biochem. J.</u> , 320:563-570 (1996).	
	363	DODART, "Immunotherapy for Alzheimer's disease: will vaccination work?" <u>Trends in Molecular Medicine</u> , 9(3):85-87 (2003).	
	422	DOERKS et al., "Protein annotation: detective work for function prediction," <u>Trends in Genetics</u> , 14(6):248-250 (1998).	
	318	DU et al., "Reduced levels of amyloid beta-peptide antibody in Alzheimer disease," <u>Neurology</u> , 57(5):801-5 (2001).	
	407	ECK et al., <i>Goodman and Gilman's The pharmacological basis of therapeutics</i> , Chapter 5, pages 77-101 (1996)	
	328	FELSENSTEIN et al., "Transgenic Rat and In-Vitro Studies of B-Amyloid Precursor Protein Processing," <u>Alzheimer's and Parkinson's Diseases</u> , Hanin et al. Ed., pp 401-409, Plenum Press, New York, (1995).	
	423	FONSECA et al., "The Presence of Isoaspartic Acid in $\beta$ -Amyloid Plaques Indicates Plaque Age," <u>Experimental Neurology</u> , 157(2):277-288 (1999).	
	386	FRAUTSCHY et al., "Effects of injected Alzheimer $\beta$ -amyloid cores in rat brain," <u>PNAS</u> , 88:8362-8366 (1991).	
	364	FURLAN et al., "Vaccination with amyloid- $\beta$ peptide induces autoimmune encephalomyelitis in C57/BL6 mice," <u>Brain</u> , 126:285-291 (2003).	
	388	GOLDFARB et al., "The Transmissible Spongiform Encephalopathies," <u>Ann. Rev. Med.</u> , 46:57-65 (1995).	
	424	GOLDSBY et al., "Vaccines," Chapter 18 from <i>Immunology</i> , 4th Edition, W.H. Freeman and Company, New York, pages 449-465.	
V	397	GOLDSTEINS et al., "Goldsteins et al., Exposure of cryptic epitopes on transthyretin only in amypoid and in amyloidogenic mutants," <u>PNAS</u> , 96:3108-3113 (1999).	
KAB	413	HOLTZMAN et al., "A $\beta$ immunization and anti-A $\beta$ antibodies: potential therapies for the prevention and treatment of Alzheimer's disease," <u>Advanced Drug Delivery Reviews</u> , 54:1603-1613 (2002).	

Examiner Signature	K. Ballard	Date Considered	10/3/06
--------------------	------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60195301 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 9

### Complete if Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk
Art Unit	1647
Examiner Name	Nichols
Attorney Docket Number	15270J-004743US

KAB	374	JAKES et al., "Characterisation of an Antibody Relevant to the Neuropathology of Alzheimer Disease," <u>Alzheimer Disease and Associated Disorders</u> , 9(1):47-51, Raven Press, Ltd., New York (1995).	
	308	JANUS et al., "A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease," <u>Nature</u> , 408(6815):979-82 (2000).	
	334	JOBLING and HOLMES, "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," <u>Molecular Microbiology</u> , 5(7):1755-1767 (1991).	
	371	JOHNSTONE et al., Nuclear and Cytoplasmic Localization of the $\beta$ -Amyloid Peptide (1-43) in Transfected 293 Cells," <u>Biochemical and Biophysical Research Communications</u> , 220:710-718 (1996).	
	347	JORBECK et al., "Artificial <i>Salmonella</i> Vaccines: <i>Salmonella typhimurium</i> O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis," <u>Infection and Immunity</u> , May:497-502 (1981).	
	434	KELLY, J. W., "Alternative conformations of amyloidogenic proteins govern their behavior," <u>Current Opinion in Structural Biology</u> , 6:11-17 (1996).	
	389	KOVÁCS et al., "Mutations of the Prion Protein Gene Phenotypic Spectrum," <u>J. Neurol.</u> , 249:1567-1582 (2002).	
	408	MARSHALL, E., "Gene Therapy's Growing Pains," <u>Science</u> , 269:1050-1055 (1995).	
	335	MASLIAH et al., " $\beta$ -Amyloid peptides enhance $\alpha$ -synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease," <u>PNAS</u> , 98(21):12245-12250 (2001).	
	309	MATTSON, Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. <u>Physiol Rev.</u> 77(4):1081-132 (1997).	
	310	MERLUZZI, et al., "Humanized antibodies as potential drugs for therapeutic use," <u>Adv Clin Path.</u> , 4(2):77-85 (2000).	
	367	MONSONEGO et al., "Immune hyporesponsiveness to amyloid $\beta$ -peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease," <u>PNAS</u> , 98(18):10273-10278 (2001).	
KAB	311	MORGAN, et al., "A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," <u>Nature</u> , 408(6815):982-5 (2000).	

Examiner  
Signature

K. Ballard

Date  
Considered

10/3/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60195301 v1



PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/724,319		
		Filing Date	November 27, 2000		
		First Named Inventor	Schenk		
		Art Unit	1647		
		Examiner Name	Nichols		
Sheet	6	of	9	Attorney Docket Number	15270J-004743US


KAB	359	MUNCH et al., "Potential neurotoxic inflammatory response to A $\beta$ vaccination in humans," (2002) <u>J. Neural Transm.</u> , 109:1081-1087.	
	355	MUNSON ed., "Principals of Pharmacology: Basic Concepts & Clinical Applications," (1995), 47-48, Chapman & Hall, New York, New York.	
	354	MUTSCHLER et al., "Drug Actions: Basic Principles and Therapeutic Aspects," (1995) 7, 11-12, <u>medpharm</u> Scientific Publishers, Stuttgart, Germany.	
	439	NALBANTOGLU, J., "Beta-amyloid protein in Alzheimer's disease," <u>Can. J. Neurol. Sci.</u> , 18(3 suppl.):424-427 (1991), abstract only	
	425	NGO et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," pages 492-495 from Chapter 14 of <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz et al., eds., Birkhauser Boston (1994).	
	350	NICOLL et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid- $\beta$ peptide: a case report," <u>Nature Medicine</u> , 9(4):448-452 (April 2003).	
	329	NIEMANN, "Transgenic farm animals get off the ground," <u>Transgenic Research</u> 7:73-75 (1998).	
	409	ORKIN et al., <i>Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy</i> , December 7, 1995	
	398	PALHA et al., "Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidotic polyneuropathy," <u>J. Mol. Med.</u> , 7:703-707 (2001).	
	406	PAN et al., "Antibodies to $\beta$ -Amyloid Decrease the Blood-to-Brain Transfer of $\beta$ -Amyloid Peptide," <u>Exp. Biol. Med.</u> , 227(8):609-615 (2002).	
	437	PERSSON et al., "IgG subclass-associated affinity differences of specific antibodies in humans," <u>J. Immunology</u> , 140(11):3875-3879 (1988), abstract only	
	336	PERUTZ et al., "Amyloid fibers are water-filled nanotubes," <u>PNAS</u> , 99(8):5591-5595 (2002).	
V	394	PRUSINER et al., "Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies," <u>PNAS</u> , 90:10608-10612 (1993).	
KAB	304	RASO, V.A., Grant application # 1-R43-AG-5746-01 (non-redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).	Do NOT PRINT: NO DATE.

Examiner Signature	K. Ballard	Date Considered	10/3/06
--------------------	------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60195301 v1



→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 7 of 9

**Complete if Known**

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk
Art Unit	1647
Examiner Name	Nichols
Attorney Docket Number	15270J-004743US

HAB	312	SCHENK et al., "Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier," <u>DNA Cell Biol.</u> , 20(11):679-81 (2001).	
	414	SCHENK, D., "Amyloid- $\beta$ immunotherapy for Alzheimer's disease: the end of the beginning," <u>Nature Reviews</u> , 3:824-828 (2002).	
	313	SELKOE, "The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease," <u>Trends Cell Biol.</u> , 8(11):447-53 (1998).	
	330	SIGMUND, "Viewpoint: Are Studies in Genetically Altered Mice Out of Control," <u>Arterioscler Thromb Vasc Biol.</u> , 20:1425-1429 (2000).	
	396	SIGURDSSON et al., "Anti-prior antibodies for prophylaxis following prion exposure in mice," <u>Neurosciences Letters</u> , 336:185-187 (2003).	
	384	SIGURDSSON et al., "Immunization Delays the Onset of Prion Disease in Mice," <u>American Journal of Pathology</u> , 161:13-17 (2002).	
	314	SIGURDSSON, et al., "In vivo reversal of amyloid-beta lesions in rat brain," <u>J Neuropathol Exp Neurol.</u> , 59(1):11-17 (2000).	
	400	SIGURDSSON et al., "A safer vaccine for Alzheimer's disease?," <u>Neurobiology of Aging</u> , 23:1001-1008 (2002).	
	426	SINGH, K. S., "Neuroautoimmunity: Pathogenic Implications for Alzheimer's Disease," <u>Gerontology</u> , 43:79-94 (1997).	
	438	SINGH, V. K., "Studies of neuroimmune markers in Alzheimer's disease," <u>Mol. Neurobiology</u> , 9(1-3):73-81 (1994), abstract only	
	315	SINHA, et al., "Recent advances in the understanding of the processing of APP to beta amyloid peptide," <u>Ann N Y Acad Sci.</u> , 920:206-8 (2000).	
	368	SIPE, "Amyloidosis," <u>Annu. Rev. Biochem.</u> , 61:947-975 (1992).	
V	337	SKOLNICK and FETROW, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <u>Trends in Biotech.</u> , 18(1):34-39 (2000).	
KAB	319	SMALL, et al. Alzheimer's disease and Abeta toxicity: from top to bottom. <u>Nat Rev Neurosci.</u> 2(8):595-8 (2001).	

Examiner  
Signature

K. Ballard

Date  
Considered


10/3/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60195301 v1



PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/724,319		
		Filing Date	November 27, 2000		
		First Named Inventor	Schenk		
		Art Unit	1647		
		Examiner Name	Nichols		
Sheet	8	of	9	Attorney Docket Number	15270J-004743US

KAB	427	SMITH et al., "The challenges of genome sequence annotation or 'The devil is in the details,'" <u>Nature Biotechnology</u> , 15:1222-1223 (1997).	
	411	SOLOMON et al., "The Amino Terminus of the $\beta$ -Amyloid Peptide Contains an Essential Epitope for Maintaining Its Solubility," from <i>Progress in Alzheimer's and Parkinson's Diseases</i> , edited by Fisher et al., Plenum Press, New York, pages 205-211 (1995).	
	316	SOTO, et al. Beta sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. <u>Nat Med.</u> 4(7):822-6 (1998).	
	369	SPOONER et al., "The generation and characterization of potentially therapeutic A $\beta$ antibodies in mice: differences according to strain and immunization protocol," <u>Vaccine</u> , 21:290-297 (2002).	
	338	STEIN et al., "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways," <u>The Journal of Neuroscience</u> , 22(17):7380-7388 (September 1, 2002).	
	435	STERN et al., "Antibodies to the $\beta$ -amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood," <u>FEBS Letters</u> , 264(1):43-47 (1990).	
	361	SU et al., "Intravascular infusions of soluble $\beta$ -amyloid compromise the blood-brain barrier, activate CNS Glial cells and induce peripheral hemorrhage," <u>Brain Research</u> , 818:105-107 (1999).	
	392	TAL et al., "Complete Freund's Adjuvant Immunization Prolongs Survival in Experimental Prion Disease in Mice," <u>Journal of Neuroscience Research</u> , 71:286-290 (2003).	
	399	TAN et al., "Amyloidosis," <u>Histopathology</u> , 25:403-414 (1994).	
	339	TENNENT et al., "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis," <u>PNAS</u> , 92:4299-4303 (1995).	
	375	TSUZUKI et al., "Amyloid $\beta$ protein in rat soleus in choroquine-induced myopathy using end-specific antibodies for A $\beta$ 40 and A $\beta$ 42: immunohistochemical evidence for amyloid $\beta$ protein," <u>Neuroscience Letters</u> , 2002:77-80 (1995).	
	317	VEHMAS, et al. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPsw/PS1 DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology. <u>DNA Cell Biol.</u> (11):713-21 (2001).	
KAB	428	VELAZQUEZ et al., "Aspartate residue 7 in amyloid $\beta$ -protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis," <u>Nature Medicine</u> , 3(1):77-79 (1997).	


Examiner Signature	K. Ballard	Date Considered	10/3/06
--------------------	------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60195301 v1





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/724,319		
		Filing Date	November 27, 2000		
		First Named Inventor	Schenk		
		Art Unit	1647		
		Examiner Name	Nichols		
Sheet	9	of	9	Attorney Docket Number	15270J-004743US

KAB	410	VERMA et al., "Gene therapy - promises, problems and prospects," <u>Nature</u> , 389:239-242 (1997).	
	387	WELDON et al., "Neurotoxicity of A $\beta$ Peptide: Confocal Imaging of Cellular Changes Induced by - Amyloid in Rat CNS <i>In Vivo</i> ," <u>Society for Neuroscience Abstracts</u> , 22(Part 1) (1996). ****	
	429	WELLS, J. A., "Additivity of Mutational Effects in Proteins," <u>Biochemistry</u> , 29(37):8509-8517 (1990).	
V	385	WISNIEWSKI et al., "Therapeutics in Alzheimer's and Prion Diseases," <u>Biochemical Society Transactions</u> , 30(4):-574-587 (2002).	
KAB	430	YANG et al., "Effects of Racemization on the Aggregational Properties of the Amyloid $\beta$ -Peptide in Alzheimer's Disease," abstract # 255 from American Chemical Society 214th National Meeting (1997).	

Examiner Signature	K. Ballard	Date Considered	10/3/06
-----------------------	------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60195301 v1



→

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 5

**Complete if Known**

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647 1649
Examiner Name	Christopher J. Nichols K.A. Ballard
Attorney Docket Number	15270J-004743US

**U.S. PATENT DOCUMENTS**

Examiner	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KAB	453	2002/0058267 A1	05-16-2002	Ozenberger et al.	
KAB	452	6,218,506 B1	04-17-2001	Krafft et al.	
KAB	451	5,766,846	06-16-1998	Schlossmacher et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
KAB	458	WO	02/06048 1	A1	08-08- 2002			
↓	457	WO	02/04623 7	A1	06-13- 2002			
↓	456	WO	02/02114 1	A2	03-14- 2002			
↓	455	WO	01/10900	A2	02-15- 2001			
KAB	454	WO	98/33815	A1	08-06- 1998			

Examiner  
Signature

K. Ballard

Date  
Considered

10/3/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

60274022 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 5

### Complete If Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk Dale B.
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004743US

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
KAB	484	ARENDIASH GW et al., "Behavioral assessment of Alzheimer's transgenic mice following long-term A $\beta$ vaccination: Task specificity and correlations between A $\beta$ deposition and spatial memory," <i>DNA and Cell Biology</i> , 20(11):737-744 (2001)	
	485	BACSKAI BJ et al., "Imaging of amyloid- $\beta$ deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy," <i>Nature Medicine</i> , 7(3):369-372 (2001)	
	504	BALBACH J et al., "Amyloid fibril formation by A $\beta$ <sub>16-22</sub> , a seven-residue fragment of the Alzheimer's $\beta$ -amyloid peptide, and structural characterization by solid state NMR" <i>Biochemistry</i> , vol. 39, pp. 13748-59 (2000)	
	461	BURDICK D et al., "Assembly and aggregation properties of synthetic Alzheimer's A $\beta$ amyloid peptide antigens," <i>J Biol Chem</i> , 267:546-55 (1992)	
	462	CO MS et al. "Chimeric and humanized antibodies with specificity for the CD33 antigen," <i>J Immunol</i> , 148:1149-1154 (1992)	
	469	DEMATTOS RB et al., "Peripheral anti-A $\beta$ antibody alters CNS and plasma clearance and decreases A $\beta$ burden in a mouse model of Alzheimer's disease," <i>Proc Natl Acad Sci USA</i> 98(15):8850-8855 (2001).	
	493	DEMATTOS RB et al., "Plaque-associated disruption of CSF and plasma amyloid- $\beta$ (A $\beta$ ) equilibrium in a mouse model of Alzheimer's disease," <i>J Neurochem</i> , 81:229-236, (2002)	
	486	DICKEY CA et al., "Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated $\beta$ -amyloid 1-42 peptide," <i>DNA and Cell Biology</i> , 20(11):723-729 (2001)	
	475	EL-AGNAF OM et al., "The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide," <i>Eur J Biochem</i> , 256(3):560-569 (1998)	
	501	ESLER W et al., "Point substitution in the central hydrophobic cluster of a human $\beta$ -amyloid congener disrupts peptide folding and abolishes plaque competence" <i>Biochemistry</i> , vol. 35, pp. 13914-21 (1996)	
	464	FLOOD JF et al., "An amyloid $\beta$ -Protein fragment, A $\beta$ [12-28J, equipotently impairs post-training memory processing when injected into different limbic system structures," <i>Brain Res</i> , 663(2):271-276 (1994)	
KAB	463	GHISO J et al., "Epitope map of two polyclonal antibodies that recognize amyloid lesions in patients with Alzheimer's disease," <i>Biochem J</i> , 282 (Pt 2):517-522 (1992)	

Examiner  
Signature

K. Ballard


Date  
Considered

10/3/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60274022 v1



→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 5

**Complete If Known**

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk Dale B.
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004743US

KAB	470	GIULIAN D et al., "Specific domains of $\beta$ -amyloid from Alzheimer plaque elicit neuron killing in human microglia," <u>J Neurosci</u> , 16 (19):6021-6037 (1996)	
	503	GOREVIC P et al., "Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic X ray diffraction pattern" <u>Biochem. and Biophys. Res. Commun.</u> , vol. 147, no. 2 (1987)	
	487	HAASS C et al., "Protofibrils, the unifying toxic molecule of neurodegenerative disorders?" <u>Nature Neuroscience</u> , 4(9):859-860 (2001)	
	476	HE X-Y et al., "Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P- selectin," <u>J Immunol</u> , 160:1029-1035 (1998)	
	473	HILBICH C et al., "Aggregation and secondary structure of synthetic amyloid $\beta$ A4 peptides of Alzheimer's disease" <u>J. Mol. Biol.</u> , vol. 218, pp 149-163 (1991)	
	471	HILBICH C et al., "Substitutions of hydrophobic amino acid reduce the amyloidogenicity of Alzheimer's disease $\beta$ A4 peptides" <u>J. Mol. Biol.</u> , vol. 228, pp 460-73 (1992)	
	488	KLEIN WL et al., "Targeting small A $\beta$ oligomers: the solution to an Alzheimer's disease conundrum?" <u>Trends in Neurosciences</u> , 24(4):219-224 (2001)	
	494	KOTILINEK LA et al., "Reversible memory loss in a mouse transgenic model of Alzheimer's disease," <u>J Neurosci</u> , 22(15):6331-6335 (2002)	
	465	KOUDINOV A et al., "The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma," <u>Biochem &amp; Biophys Res Commun</u> , 205:1164-1171 (1994)	
	478	KUO YM et al., "High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease," <u>Biochem Biophys Res Commun</u> , 257(3):787- 791 (1999)	
	477	LAMBERT MP et al., "Diffusible, nonfibrillar ligands derived from A $\beta$ 1-42 are potent central nervous system neurotoxins," <u>Proc Natl Acad Sci</u> , 95:6448-6453 (1998)	
	489	LAMBERT MP et al., "Vaccination with soluble A $\beta$ oligomers generates toxicity-neutralizing antibodies," <u>J Neurochem</u> , 79:595-605 (2001)	
	490	LEE VM-Y et al., "A $\beta$ immunization: Moving A $\beta$ peptide from brain to blood," <u>PNAS</u> , 98(16):8931-8932 (2001)	
	459	LEVITT M. "Molecular dynamics of native protein," <u>J. Mol Biol</u> , 168:595-620 (1983)	
KAB	481	LEVY A et al., "Immunization for Alzheimer's disease: A shot in the arm or a whiff?" <u>American Neurological Assoc</u> , 48:553-554 (2000)	

Examiner  
Signature

K. Ballard

Date  
Considered

10/3/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60274022 v1



→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/724,319
		Filing Date	November 27, 2000
		First Named Inventor	Schenk Dale B.
		Art Unit	1647
		Examiner Name	Christopher J. Nichols
		Attorney Docket Number	15270J-004743US
Sheet	4	of	5

KAB	499	LUE L et al., "Soluble $\beta$ -amyloid Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease", <u>Am. J. Pathol.</u> , 1999, 155: pp 853-62	
	502	MAGGIO J & MANTYH P "Brain Amyloid - A Physicochemical Perspective" <u>Brain Pathology</u> , vol. 6, 147-162 (1996)	
	479	MCLEAN C et al., " Soluble pool of A $\beta$ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease," <u>Amer Neurological Assoc</u> , 46:860- 866 (1999)	
	482	NASLUND J et al., "Correlation between elevated levels of amyloid $\beta$ peptide in the brain and cognitive decline," <u>J Am Med Assoc</u> , 283:1571 (2000)	
	491	PODUSLO JF et al., "Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease," <u>Neurobiol Dis</u> , 8(4):555-67 (2001)	
	460	QUEEN C et al., "A humanized antibody that binds to the interleukin 2 receptor," <u>Proc Natl Acad Sci USA</u> , 86:10029-10033 (1989)	
	497	RAGUSI C et al., "Redistribution of Imipramine from Regions of the Brain Under the Influence of Circulating Specific Antibodies" <u>J. Neurochem.</u> , Vol. 70, No. 5, pp 2099-105 (1998)	
	466	SCHWARZMAN AL et al., "Transthyretin sequesters amyloid $\beta$ protein and prevents amyloid formation," <u>Proc Natl Acad Sci</u> , 91:8368-8372, (1994)	
	505	SIMMONS L "Secondary structure of amyloid $\beta$ peptide correlates with neurotoxic activity in vitro" <u>Molecular Pharmacology</u> , vol. 45, pp 373-9 (1994)	
	508	SOTO C et al., "The $\alpha$ -helical to $\beta$ -strand transition in the amino-terminal fragment of the amyloid $\beta$ -peptide modulates amyloid formation" <u>J. Biol. Chem</u> , vol. 270, no. 7, pp 3063 67 (1995)	
	496	STRBAK V et al., Passive Immunization and Hypothalamic Peptide Secretion", <u>Neuroendocrinology</u> , 1993; 58:210-217	
	498	SUO et al., "Soluble Alzhemlers $\beta$ -amyloid constricts the cerebral vasculature in vivo" <u>Neuroscience Letters</u> 257, pp 77-80 (1998)	
	467	TABATON M et al., "Soluble amyloid $\beta$ -protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid," <u>Biochem and Biophys Res Comm</u> , 200(3):1598-1603 (1994)	
	472	TELLER J et al., "Presence of soluble amyloid $\beta$ -peptide precedes amyloid plaque formation in Down's syndrome" <u>Nature Medicine</u> , vol. 2, no. 1, pp 93-95 (1996)	
KAB	500	TJEMBERG L et al., "A molecular model for Alzheimer amyloid $\beta$ -peptide fibril formation" <u>J. Biol. Chem</u> , vol. 274, no. 18, pp 12619-25 (1999)	

Examiner Signature	K. Ballard	Date Considered	10/3/06
--------------------	------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60274022 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 5

### Complete if Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk Dale B.
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004743US

KAB	492	TOWN T et al., "Characterization of murine immunoglobulin G antibodies against human amyloid- $\beta_{1-42}$ " <u>Neurosci Lett</u> , 307:101-104 (2001)	
	495	WANG H-W et al., "Soluble oligomers of $\beta$ amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus," <u>Brain Research</u> , 924:133-140 (2002)	
	480	WANG J et al., "The levels of soluble versus insoluble brain A $\beta$ distinguish Alzheimer's disease from normal and pathologic aging," <u>Experimental Neurology</u> , 158:328-337 (1999)	
	474	WINTER G et al., "Humanized antibodies" <u>Immunology Today</u> , 14(6):243-246 (1996)	
	468	WISNIEWSKI T et al., "Alzheimer's disease and soluble A beta," <u>Neurobiol Aging</u> , 15(2):143-52 Review (1994)	
	506	WOOD, A et al., "Prolines and amyloidogenicity in fragments of the Alzheimer's peptide $\beta$ /A4" <u>Biochemistry</u> , vol. 34 pp. 724-30 (1995)	
V	507	XU S and GASKIN F "Increased incidence of anti- $\beta$ -amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease" <u>Mechanisms of Ageing and Development</u> , vol. 94, pp 213-22 (1997)	
KAB	483	ZLOKOVIC BV et al., "Clearance of amyloid $\beta$ -peptide from brain: transport or metabolism?" <u>Nature Medicine</u> , 6(7):718-719 (2000)	

Examiner Signature	K. Ballard	Date Considered	10/3/06
--------------------	------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 606. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional); <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60274022 v1

PTO/SB/08A (08-08)

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	09/724,319
		Filing Date	November 27, 2000
		First Named Inventor	Schenk, Dale B.
		Art Unit	1847-1649
		Examiner Name	Nichols- Ballard
Sheet 1 of 1	Attorney Docket Number	15270J-004743US	


U.S. PATENT DOCUMENTS					
		Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Examiner	Cite No. <sup>1</sup>	Number Kind Code <sup>2</sup> (if known)			
KAB	543	US-6,278,049 A	01/11/1994	Baker et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>8</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>

Examiner Signature	K. Ballard	Date Considered	10/3/06
-----------------------	------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 001.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

v8



→

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

### Complete if Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647-1649
Examiner Name	<del>Christopher J. Nichols</del> K.A. Ballard
Attorney Docket Number	15270J-004743US

### U.S. PATENT DOCUMENTS

Examiner	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KAB	445	5,854,215	12-29-1998	Findeis et al.	
KAB	446	5,817,626	10-06-1998	Findeis et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
KAB	447	WO	03/051374	A2	06-26-2003			
KAB	450	WO	01/18169	A3	03-15-2001			

Examiner  
Signature

K. Ballard

Date  
Considered


10/3/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
60266432 v1





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/724,319		
		Filing Date	November 27, 2000		
		First Named Inventor	Dale B. Schenk		
		Art Unit	1647		
		Examiner Name	Christopher J. Nichols		
Sheet	2	of	2	Attorney Docket Number	15270J-004743US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.); date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
KAB	448	ANDREW et al., <i>Current Protocols in Immunology</i> , 2.7.1-2.9.8 (1997).	
KAB	449	JOHNSON-WOOD et al., "Amyloid precursor protein processing and A $\beta$ <sub>42</sub> deposition in a transgenic mouse model of Alzheimer disease," <i>PNAS</i> , 94:1550-1555 (1997).	

Examiner Signature	<i>K. Ballard</i>	Date Considered	10/3/06
-----------------------	-------------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60266432 v1